Published in Int J Oncol on December 01, 2002
Redox activation of metal-based prodrugs as a strategy for drug delivery. Adv Drug Deliv Rev (2012) 1.06
Microwave synthesis of mixed ligand diimine-thiosemicarbazone complexes of ruthenium(II): biophysical reactivity and cytotoxicity. Dalton Trans (2009) 0.87
Regression of lung cancer by hypoxia-sensitizing ruthenium polypyridyl complexes. Mol Cancer Ther (2013) 0.84
Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation. J Biol Inorg Chem (2008) 0.83
Organometallic ruthenium complexes with thiosemicarbazone ligands: Synthesis, structure and cytotoxicity of [(eta-p-cymene)Ru(NS)Cl] (NS = 9-anthraldehyde thiosemicarbazones). Inorg Chem Commun (2009) 0.80
Synthesis, spectral characterization, and antiproliferative studies of mixed ligand titanium complexes of adamantylamine. Bioinorg Chem Appl (2014) 0.80
Antimetastatic activity of novel ruthenium (III) pyridine complexes. Cancer Med (2016) 0.76
Cellular and cell-free studies of catalytic DNA cleavage by ruthenium polypyridyl complexes containing redox-active intercalating ligands. Chem Sci (2017) 0.75
Reaction of the Anticancer Organometallic Ruthenium Compound, [(eta-p-Cymene)Ru(ATSC)Cl]PF(6) with Human Serum Albumin. Int J Inorg Chem (2010) 0.75
Hypoxia-selective inhibition of angiogenesis development by NAMI-A analogues. Biometals (2016) 0.75
The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials. Chem Soc Rev (2017) 0.75
A review on usnic acid, an interesting natural compound. Naturwissenschaften (2002) 1.43
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J Med Chem (2005) 1.35
Pluripotency regulators in human mesenchymal stem cells: expression of NANOG but not of OCT-4 and SOX-2. Stem Cells Dev (2010) 1.27
Metal-based antitumour drugs in the post genomic era. Dalton Trans (2006) 1.24
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res (2007) 1.21
Ruthenium antimetastatic agents. Curr Top Med Chem (2004) 1.20
Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. Int J Oncol (2008) 1.18
Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. PLoS One (2010) 1.16
Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru(L)2Cl2] (L= o-tolylazopyridine and 4-methyl-2-phenylazopyridine) in comparison to [Ru(azpy)2Cl2]. J Biol Inorg Chem (2004) 1.05
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs. Dalton Trans (2011) 1.05
Half-sandwich Ru II[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: preparation, structural characterization and in vitro cytotoxic activity. J Inorg Biochem (2008) 1.02
Metal-based inhibition of poly(ADP-ribose) polymerase--the guardian angel of DNA. J Med Chem (2011) 0.97
MAZ-binding G4-decoy with locked nucleic acid and twisted intercalating nucleic acid modifications suppresses KRAS in pancreatic cancer cells and delays tumor growth in mice. Nucleic Acids Res (2013) 0.94
In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. Mol Imaging (2009) 0.94
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. Invest New Drugs (2014) 0.94
Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. Clin Cancer Res (2003) 0.93
Self-assembled metallacycles with pyrazine edges: a new example in which the unexpected molecular triangle prevails over the expected molecular square. Inorg Chem (2007) 0.91
New cationic and neutral Ru(II)- and Os(II)-dmso carbonyl compounds. Inorg Chem (2013) 0.91
Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity. Biochem Pharmacol (2012) 0.91
The proline-rich peptide Bac7(1-35) reduces mortality from Salmonella typhimurium in a mouse model of infection. BMC Microbiol (2010) 0.90
Synthesis and structural, spectroscopic, and electrochemical characterization of new ruthenium dimethyl sulfoxide nitrosyls. Inorg Chem (2002) 0.90
Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms. J Med Chem (2007) 0.90
The anti-metastatic agent imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway. Arch Biochem Biophys (2002) 0.89
C1q as a unique player in angiogenesis with therapeutic implication in wound healing. Proc Natl Acad Sci U S A (2014) 0.89
Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin Cancer Res (2004) 0.89
An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies. Curr Pharm Des (2008) 0.88
Replacement of chlorides with dicarboxylate ligands in anticancer active Ru(II)-DMSO compounds: a new strategy that might lead to improved activity. Inorg Chem (2007) 0.87
Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation. Eur J Biochem (2002) 0.87
A categorization of metal anticancer compounds based on their mode of action. Dalton Trans (2009) 0.86
Analysis of the cytotoxicity of synthetic antimicrobial peptides on mouse leucocytes: implications for systemic use. J Antimicrob Chemother (2002) 0.86
Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. Dalton Trans (2007) 0.86
Linking the future of anticancer metal-complexes to the therapy of tumour metastases. Chem Soc Rev (2015) 0.85
New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. PLoS One (2013) 0.85
Ruthenium-porphyrin conjugates with cytotoxic and phototoxic antitumor activity. J Med Chem (2010) 0.85
Synthetic strategies and structural aspects of metal-mediated multiporphyrin assemblies. Acc Chem Res (2006) 0.85
Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes. J Med Chem (2006) 0.84
New half sandwich Ru(II) coordination compounds for anticancer activity. Dalton Trans (2012) 0.83
Metyrapone prevents cortisone-induced preadipocyte differentiation by depleting luminal NADPH of the endoplasmic reticulum. Biochem Pharmacol (2008) 0.83
Multi-potent progenitors in freshly isolated and cultured human mesenchymal stem cells: a comparison between adipose and dermal tissue. Cell Tissue Res (2011) 0.83
The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation. J Inorg Biochem (2004) 0.83
Trinuclear metallacycles: metallatriangles and much more. Chem Rev (2008) 0.83
Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation. J Biol Inorg Chem (2008) 0.83
NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels. Dalton Trans (2014) 0.82
Platinum(II) complexes with antitumoral/antiviral aromatic heterocycles: effect of glutathione upon in vitro cell growth inhibition. J Med Chem (2005) 0.82
Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: a preclinical study. Invest New Drugs (2004) 0.82
Preclinical combination therapy of the investigational drug NAMI-A(+) with doxorubicin for mammary cancer. Invest New Drugs (2014) 0.81
Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma. Curr Clin Pharmacol (2010) 0.81
Nitric oxide-mediated activity in anti-cancer photodynamic therapy. Nitric Oxide (2013) 0.81
Profiling the molecular mechanism of fullerene cytotoxicity on tumor cells by RNA-seq. Toxicology (2013) 0.81
The PDT activity of free and pegylated pheophorbide a against an amelanotic melanoma transplanted in C57/BL6 mice. Invest New Drugs (2012) 0.80
Ruthenium anticancer drugs. Met Ions Biol Syst (2004) 0.80
Antiviral properties and cytotoxic activity of platinum(II) complexes with 1,10-phenanthrolines and acyclovir or penciclovir. J Inorg Biochem (2004) 0.80
1-(2-Picolyl)-substituted 1,2,3-triazole as novel chelating ligand for the preparation of ruthenium complexes with potential anticancer activity. Dalton Trans (2011) 0.80
Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. J Hematol Oncol (2014) 0.80
Anticancer activity of cationic porphyrins in melanoma tumour-bearing mice and mechanistic in vitro studies. Mol Cancer (2014) 0.80
Molecular structure, solution chemistry and biological properties of the novel [ImH][trans-IrCl(4)(Im)(DMSO)], (I) and of the orange form of [(DMSO)(2)H][trans-IrCl(4)(DMSO)(2)], (II), complexes. J Inorg Biochem (2003) 0.79
Wavelength-dependent electron and energy transfer pathways in a side-to-face ruthenium porphyrin/perylene bisimide assembly. J Am Chem Soc (2005) 0.79
Electrochemical measurements confirm the preferential bonding of the antimetastatic complex [ImH][RuCl(4)(DMSO)(Im)] (NAMI-A) with proteins and the weak interaction with nucleobases. J Inorg Biochem (2004) 0.79
Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines. J Pharmacol Exp Ther (2003) 0.79
Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells. Cancer Chemother Pharmacol (2002) 0.78
Solution, solid state and biological characterization of ruthenium(III)-DMSO complexes with purine base derivatives. J Inorg Biochem (2004) 0.78
Metallacycles of porphyrins as building blocks in the construction of higher order assemblies through axial coordination of bridging ligands: solution- and solid-state characterization of molecular sandwiches and molecular wires. J Am Chem Soc (2002) 0.78
Novel water-soluble (99m)Tc(I)/Re(I)-porphyrin conjugates as potential multimodal agents for molecular imaging. J Inorg Biochem (2013) 0.78
fac-[Re(CO)3(dmso-O)3](CF3SO3): a new versatile and efficient Re(I) precursor for the preparation of mono and polynuclear compounds containing fac-[Re(CO)3]+ fragments. Dalton Trans (2006) 0.78
New uses for old drugs: attempts to convert quinolone antibacterials into potential anticancer agents containing ruthenium. Inorg Chem (2013) 0.78
Two-point self-coordination of a dizinc(II) bispyridylporphyrin ruthenium complex leading selectively to a discrete molecular assembly: solution and solid-state characterization. Chemistry (2002) 0.77
Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A. J Pharm Biomed Anal (2002) 0.77
RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A. Metallomics (2015) 0.77
TGFbeta1 regulation and collagen-release-independent connective tissue re-modelling by the ruthenium complex NAMI-A in solid tumours. J Inorg Biochem (2004) 0.77
Inhibition of human pancreatic cell line MIA PaCa2 proliferation by HA-But, a hyaluronic butyric ester: a preliminary report. Pancreas (2008) 0.77
Conjugated PDT drug: photosensitizing activity and tissue distribution of PEGylated pheophorbide a. Cancer Biol Ther (2010) 0.77
Intratumoral NAMI-A treatment triggers metastasis reduction, which correlates to CD44 regulation and tumor infiltrating lymphocyte recruitment. J Pharmacol Exp Ther (2004) 0.77